Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Total Liabilities (2024 - 2025)

Prelude Therapeutics' Total Liabilities history spans 2 years, with the latest figure at $72.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 64.97% year-over-year to $72.7 million; the TTM value through Dec 2025 reached $72.7 million, up 64.97%, while the annual FY2025 figure was $72.7 million, 64.97% up from the prior year.
  • Total Liabilities for Q4 2025 was $72.7 million at Prelude Therapeutics, up from $36.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $72.7 million in Q4 2025 and bottomed at $36.2 million in Q3 2025.